1
|
Exploring and Verifying the Mechanism and Targets of Shenqi Pill in the Treatment of Nonalcoholic Steatohepatitis via Network Pharmacology and Experiments. J Immunol Res 2022; 2022:6588144. [PMID: 35733920 PMCID: PMC9207021 DOI: 10.1155/2022/6588144] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2022] [Revised: 04/08/2022] [Accepted: 05/18/2022] [Indexed: 11/30/2022] Open
Abstract
Shenqi pill (SQP), a famous traditional Chinese medicine (TCM) herbal formula derived from Jinguiyaolue (Synopsis of Prescriptions of the Golden Chamber), has long been used to treat kidney yang deficiency syndrome. According to the TCM treatment principle that the liver and kidney are homologies, the clinical use of SQP in the treatment of nonalcoholic steatohepatitis (NASH) has achieved a good effect. However, the active targeted genes and underlying mechanism remain unclear. In this study, we aimed to explore the treatment mechanism of SQP in NASH rats, which may further contribute to the in-depth exploration of SQP in clinical applications. Network pharmacology analysis was used to screen the target genes of SQP for NASH treatment based on public databases. Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis, and protein–protein interaction (PPI) analysis were used to search for crucial target genes and mechanisms. UPLC–MS/MS was used to verify the active compounds of the SQP screened. The hepatic pathology and biochemical indicators of rats were used to judge the modeling results and the curative effect of SQP. Western blotting and qRT–PCR were used to verify the expression of crucial target genes at the protein and RNA levels, respectively. Network pharmacology analysis and bioinformatics analysis showed that PTGS2, JUN, MYC, and CDKN1A might be crucial target genes in the primary mechanism of SQP in treating NASH and improving the inflammatory response. The UPLC–MS/MS results confirmed that the hub active compound, quercetin, screened out through the TCMSP database, is indeed present in SQP. Hepatic injury and lipid metabolism indicators of NASH rats were significantly improved after SQP treatment. The results of WB and qRT–PCR showed that the expression of PTGS2, JUN, MYC, and CDKN1A was higher in NASH rats than in normal rats and decreased after SQP treatment. The expression of inflammatory cytokines (IL-1β, IL-6, TNF-α) was reduced after SQP treatment, which confirmed that SQP could improve hepatic inflammation in rats. These results suggested that SQP could ameliorate NASH in rats, and that quercetin may be the critical active compound that exerts the therapeutic effect.
Collapse
|
2
|
Pan X, Xu K, Xiong R, Chen ZM, Hu CJ, Feng J, Li WB. Therapeutic Effect of Ershen Pill () Extract on Pi (Spleen)-Shen (Kidney) Yang Deficiency-Induced Diarrhea in Rat Model. Chin J Integr Med 2018; 25:536-542. [PMID: 29564802 DOI: 10.1007/s11655-017-2766-4] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2014] [Accepted: 04/12/2016] [Indexed: 10/17/2022]
Abstract
OBJECTIVE To investigate whether Ershen Pill (ESP, ) could alleviate the symptom of Pi (Spleen)-Shen (Kidney) yang deficiency (PSYD)-induced diarrhea in rat model and explore its anti-diarrhea mechanism. METHODS Seventy-five Sprague-Dawley rats were divided into 5 groups by a random number table, including control, positive, model, low-dose (LD) and high-dose (HD) ESP groups, 15 rats in each group. All the rats, except those in the control group, were developed PSYD induced-diarrhea based on its pathology and etiology. The rats in positive, LD and HD ESP groups were treated with Shenling Baizhu Pill (), LD (1.05 g/kg) or HD (3.50 g/kg) ESP petroleum ether extract once a day for 2 weeks, respectively. Body weight change and diarrhea index were measured. The histology scores of the kidney were evaluated via hematoxylin and eosin (HE) staining. Aquaporin-3 (AQP3) expression in the colon was analyzed by immunofluorescence, quantitative reverse transcription-polymerase chain reaction (qRT-PCR) and Western blot, respectively. RESULTS Compared with the model group, oral administration of LD and HD ESP prevented body weight loss and inhibited diarrhea after 2-week treatment (P<0.05). Kidney deterioration was impeded, and the histology score in LD and HD ESP groups were 8.2 and 10.5, respectively, which were both higher than those in the model group (P<0.05). In addition, ESP treatment alleviated rat colitis, and HD ESP significantly improved the AQP3 positive staining intensity in the colon tissue compared with the model group. The result from Western blot revealed that AQP3 protein synthesis in colon tissue of LD and HD ESP groups increased by 2.1- and 5.9-fold compared with the model group (P<0.05). qRT-PCR result showed that AQP3 gene expression in the HD ESP group was also up-regulated by 2.5-fold normalized to the model group (P<0.05). CONCLUSION ESP extract effectively alleviates the symptoms of PSYD and relieves PSYD-induced diarrhea by improving AQP3 synthesis in the colon.
Collapse
Affiliation(s)
- Xin Pan
- College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, 610075, China.,College of Pharmacy, South Central University for Nationalities, Wuhan, 430074, China
| | - Kang Xu
- National Innovation and Attracting Talents "111" Base, Bioengineering College, Chongqing University, Chongqing, 400030, China.,University of California, Berkeley-Chongqing University Joint PhD. Student Program in Bioengineering, Stanley Hall, Berkeley, CA, 94720, USA
| | - Rui Xiong
- College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, 610075, China
| | - Zhi-Min Chen
- College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, 610075, China
| | - Chang-Jiang Hu
- College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, 610075, China.,Key Research Institute of Quality and Efficacy Evaluation of Traditional Chinese Medicine Formula, State Administration of Traditional Chinese Medicine, Chengdu, 610075, China
| | - Jian Feng
- Key Research Institute of Quality and Efficacy Evaluation of Traditional Chinese Medicine Formula, State Administration of Traditional Chinese Medicine, Chengdu, 610075, China
| | - Wen-Bin Li
- Key Research Institute of Quality and Efficacy Evaluation of Traditional Chinese Medicine Formula, State Administration of Traditional Chinese Medicine, Chengdu, 610075, China.
| |
Collapse
|